KalVista Pharmaceuticals, Inc. (KALV)
Data as of , from SEC Form 4 filings.
See up to 3 months of KALV. The 7-day demo opens the 1M and 3M ranges and puts KALV on your watchlist.
Start 7-day demoLatest KALV insider trades
About KalVista Pharmaceuticals, Inc. (KALV)
The SEC lists KalVista Pharmaceuticals, Inc. under CIK 0001348911, in pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
KALV Form 4 activity by transaction type, last 90 days
No Form 4 activity for KALV in the last 90 days.
KALV insider transactions (Form 4)
8889 Form 4 filings on record, the earliest from Oct 4, 2024, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | Open-market sale | Common Stock | 174,485 | $16.95 footnote F1 | $2.96M | |
| Venrock Healthcare Capital Partners III, L.P. | Open-market sale | Common Stock | 160 | $17.53 footnote F4 | $3K | |
| Venrock Healthcare Capital Partners III, L.P. | Open-market sale | Common Stock | 21,386 | $17.76 footnote F6 | $380K | |
| Venrock Healthcare Capital Partners III, L.P. | Open-market sale | Common Stock | 15,417 | $18.82 footnote F8 | $290K | |
| Venrock Healthcare Capital Partners III, L.P. | Open-market sale | Common Stock | 3,183 | $19.12 footnote F10 | $61K | |
| ||||||
| Option exercise | Restricted Stock Unit | 15,625 | $0.00 | - | ||
| Option exercise | Common Stock | 15,625 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 6,693 | $16.08 footnote F3 | $108K | ||
| ||||||
| Option exercise | Common Stock | 6,250 | - footnote F1 | - | ||
| Option exercise | Common Stock | 5,000 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 5,354 | $15.57 footnote F3 | $83K | ||
| Option exercise | Restricted Stock Unit | 6,250 | $0.00 | - | ||
| Option exercise | Restricted Stock Unit | 5,000 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 23,250 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 10,034 | $15.57 footnote F3 | $156K | ||
| Option exercise | Restricted Stock Unit | 23,250 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 3,750 | - footnote F1 | - | ||
| Option exercise | Common Stock | 3,125 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 4,347 | $15.57 footnote F3 | $68K | ||
| Option exercise | Restricted Stock Unit | 3,750 | $0.00 | - | ||
| Option exercise | Restricted Stock Unit | 3,125 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 6,250 | - footnote F1 | - | ||
| Option exercise | Common Stock | 5,000 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 3,975 | $15.57 footnote F3 | $62K | ||
| Option exercise | Restricted Stock Unit | 6,250 | $0.00 | - | ||
| Option exercise | Restricted Stock Unit | 5,000 | $0.00 | - | ||
| ||||||
| Brian Piekos - Officer | Option exercise | Common Stock | 5,000 | - footnote F1 | - | |
| Brian Piekos - Officer | Open-market sale | Common Stock | 1,767 | $15.57 footnote F3 | $28K | |
| Brian Piekos - Officer | Option exercise | Restricted Stock Unit | 5,000 | $0.00 | - | |
| ||||||
| Option exercise | Common Stock | 2,419 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 1,038 | $15.00 | $16K | ||
| Option exercise | Restricted Stock Unit | 2,419 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 2,419 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 1,163 | $15.00 | $17K | ||
| Option exercise | Restricted Stock Unit | 2,419 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 1,774 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 1,109 | $15.00 | $17K | ||
| Option exercise | Restricted Stock Unit | 1,774 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 7,120 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 3,354 | $15.70 | $53K | ||
| Option exercise | Restricted Stock Unit | 7,120 | $0.00 | - | ||
| ||||||
| Bilal Arif - Officer | Grant or award | Restricted Stock Unit | 49,000 | $0.00 | - | |
| Grant or award | Restricted Stock Unit | 100,000 | $0.00 | - | ||
| Brian Piekos - Officer | Grant or award | Restricted Stock Unit | 100,000 | $0.00 | - | |
| Grant or award | Restricted Stock Unit | 100,000 | $0.00 | - | ||
| Grant or award | Restricted Stock Unit | 325,000 | $0.00 | - | ||
| Option exercise | Common Stock | 6,250 | - footnote F1 | - | ||
| Option exercise | Common Stock | 5,000 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 3,813 | $13.45 | $51K | ||
| Option exercise | Restricted Stock Unit | 6,250 | $0.00 | - | ||
| Option exercise | Restricted Stock Unit | 5,000 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 6,250 | - footnote F1 | - | ||
| Option exercise | Common Stock | 5,000 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 5,296 | $13.45 | $71K | ||
| Option exercise | Restricted Stock Unit | 6,250 | $0.00 | - | ||
| Option exercise | Restricted Stock Unit | 5,000 | $0.00 | - | ||
| ||||||
| Brian Piekos - Officer | Option exercise | Common Stock | 15,000 | - footnote F1 | - | |
| Brian Piekos - Officer | Open-market sale | Common Stock | 4,471 | $13.45 | $60K | |
| Brian Piekos - Officer | Option exercise | Restricted Stock Unit | 15,000 | $0.00 | - | |
| ||||||
| Option exercise | Common Stock | 3,750 | - footnote F1 | - | ||
| Option exercise | Common Stock | 3,125 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 4,331 | $13.45 | $58K | ||
| Option exercise | Restricted Stock Unit | 3,750 | $0.00 | - | ||
| Option exercise | Restricted Stock Unit | 3,125 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 23,250 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 10,940 | $13.45 | $147K | ||
| Option exercise | Restricted Stock Unit | 23,250 | $0.00 | - | ||
| ||||||
| Option exercise | Employee Stock Option (Right to Buy) | 87,390 | $0.00 | - | ||
| Option exercise | Common Stock | 87,390 | $0.00 | $376 | ||
| Option exercise | Restricted Stock Unit | 4,028 | $0.00 | - | ||
| Option exercise | Common Stock | 6,447 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 3,075 | $14.48 footnote F3 | $45K | ||
| Option exercise | Restricted Stock Unit | 2,419 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 4,205 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 2,683 | $14.48 footnote F3 | $39K | ||
| Option exercise | Restricted Stock Unit | 1,774 | $0.00 | - | ||
| Option exercise | Restricted Stock Unit | 2,431 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 9,364 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 4,466 | $14.48 footnote F3 | $65K | ||
| Option exercise | Restricted Stock Unit | 2,419 | $0.00 | - | ||
| Option exercise | Restricted Stock Unit | 6,945 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 7,120 | - footnote F1 | - | ||
| Open-market sale | Common Stock | 3,328 | $11.55 | $38K | ||
| Option exercise | Restricted Stock Unit | 7,120 | $0.00 | - | ||
| ||||||
| Bilal Arif - Officer | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| Patrick Treanor | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Grant or award | Stock Option (right to buy) | 45,000 | $0.00 | - | ||
| William Fairey | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
Recent KALV Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
KALV insider trading FAQ
What is the latest insider trade for KALV?
KalVista Pharmaceuticals, Inc. (KALV) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-11. The full record for KALV runs to 89 Form 4 filings, the earliest from 2024-10-04. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying KALV stock?
No insider purchases of KALV were filed in the last 90 days.
How many insiders are selling KALV stock?
No insider sales of KALV were filed in the last 90 days. 60 sales are on record for this company.
Where can I see KALV SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects KALV Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Nancy Stuart view on EDGAR
- - Brian Jg Pereira view on EDGAR
- - William Fairey view on EDGAR
- - Paul K. Audhya view on EDGAR
- - Bethany Sensenig view on EDGAR
- - Patrick Treanor view on EDGAR
- - Nicole Sweeny view on EDGAR
- - Bilal Arif view on EDGAR
- - Laurence Reid view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where KALV's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow KALV with a 7-day demo
- KALV on your watchlist
- Every KALV Form 4 filing on record
- Up to 3 months of KALV price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive